Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before. The researchers think that a combination of axitinib and nivolumab may help people with this disease because both drugs target and block proteins that play a role in cancer cell survival and growth. The researchers think the drugs may be more effective if given in combination rather than on their own.

Trial Details

NCT ID
NCT05384496
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Mucosal Melanoma Melanoma
Interventions
  • Nivolumab and/or Ipilimumab
  • Stereotactic Body Radiation Therapy (SBRT)
  • axitinib
Locations (sample)
  • Harrison, New York, United States|40.96899,-73.71263
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Histologic diagnosis of unresectable or advanced mucosal melanoma arising from the head/neck (e.g. sinonasal, oral cavity, conjunctival), gastroint…
  • Measurable disease
  • Initial study entry: Subjects must have at least 1 extracranial, unresectable, non-bony lesion that is measurable radiographically (based on RECIST…
  • Triplet arms: assessable disease required. RECIST 1.1 measurable disease is not required.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Mucosal Melanoma Melanoma Trials on Trialify →